Reaction
Immune-Mediated Cholangitis reporting signals
As of the last recalculation, Immune-Mediated Cholangitis appears in 336 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is NIVOLUMAB (PRR 183.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Nivolumab | 155 | 183.5 | 183.8 |
| Pembrolizumab | 134 | 130.6 | 130.7 |
| Ipilimumab | 65 | 115.4 | 115.6 |
| Durvalumab | 22 | 71.6 | 71.7 |
| Ado-Trastuzumab Emtansine | 6 | 44.9 | 44.9 |
| Lenvatinib | 22 | 44.4 | 44.4 |
| Pemetrexed Disodium | 23 | 40.1 | 40.1 |
| Pemetrexed | 12 | 35.9 | 35.9 |
| Suvorexant | 4 | 19.3 | 19.3 |
| Atezolizumab | 11 | 18.1 | 18.1 |